FCRL5 protein in multiple sclerosis and treatment response
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at a protein called FCRL5 in your blood to see if it is linked to multiple sclerosis and how well treatments work. It also includes people with Sjögren's syndrome and healthy volunteers for comparison. You may be asked to give blood samples and answer some questions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You either have multiple sclerosis, Sjögren's syndrome, or you are a healthy volunteer.
- If you have multiple sclerosis, you must not have had a relapse in the last 3 months.
- You cannot be taking immune-suppressing drugs or have taken corticosteroids in the last 3 months.
- You must be able to sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks specific proteins in spinal fluid to see whether they can predict how multiple sclerosis (or related symptoms like optic neuritis) may go over time. It may help doctors better estimate prognosis using results from tests you may already be having.
This study looks at different immune cells in blood and, sometimes, spinal fluid (CSF) to understand what’s driving multiple sclerosis (MS) or early MS-like symptoms. Your participation may help researchers better explain the disease and potentially improve how it’s diagnosed or treated.
This study looks at genetic information and blood test signals to understand why some people with early MS develop a worse outcome. It may help doctors predict who is at higher risk and better understand disease mechanisms.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.